(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 4.1% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.24%.
Supernus Pharmaceuticals's revenue in 2025 is $667,997,000.On average, 3 Wall Street analysts forecast SUPN's revenue for 2025 to be $35,088,864,703, with the lowest SUPN revenue forecast at $34,842,342,393, and the highest SUPN revenue forecast at $35,318,814,085. On average, 3 Wall Street analysts forecast SUPN's revenue for 2026 to be $38,418,735,552, with the lowest SUPN revenue forecast at $38,184,922,886, and the highest SUPN revenue forecast at $38,668,113,332.
In 2027, SUPN is forecast to generate $42,279,052,089 in revenue, with the lowest revenue forecast at $41,415,524,133 and the highest revenue forecast at $42,714,483,387.